CO2021003944A2 - Moduladores de monoacilglicerol lipasa - Google Patents
Moduladores de monoacilglicerol lipasaInfo
- Publication number
- CO2021003944A2 CO2021003944A2 CONC2021/0003944A CO2021003944A CO2021003944A2 CO 2021003944 A2 CO2021003944 A2 CO 2021003944A2 CO 2021003944 A CO2021003944 A CO 2021003944A CO 2021003944 A2 CO2021003944 A2 CO 2021003944A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- disorders
- formula
- monoacylglycerol lipase
- depression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Compuestos fusionados de la Fórmula (I) y Fórmula (II), composiciones farmacéuticas que los contienen, métodos para fabricarlos y métodos para usarlos que incluyen métodos para tratar estados de enfermedad, trastornos y afecciones asociados con la modulación de la MGL, tales como aquellos asociados con dolor, trastornos psiquiátricos, trastornos neurológicos (que incluyen, pero no se limitan a, trastorno depresivo mayor, depresión resistente al tratamiento, depresión ansiosa, trastorno bipolar), cánceres y afecciones oculares. y ; En donde R1, R2, R2a, R3, R3a, R4, y R4a se definen en la presente descripción.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862738600P | 2018-09-28 | 2018-09-28 | |
PCT/IB2019/058240 WO2020065613A1 (en) | 2018-09-28 | 2019-09-27 | Monoacylglycerol lipase modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021003944A2 true CO2021003944A2 (es) | 2021-04-19 |
Family
ID=68109428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0003944A CO2021003944A2 (es) | 2018-09-28 | 2021-03-29 | Moduladores de monoacilglicerol lipasa |
Country Status (23)
Country | Link |
---|---|
US (3) | US20200102303A1 (es) |
EP (1) | EP3856178A1 (es) |
JP (1) | JP2022502424A (es) |
KR (1) | KR20210069080A (es) |
CN (1) | CN113164459A (es) |
AU (1) | AU2019350624A1 (es) |
BR (1) | BR112021005896A2 (es) |
CA (1) | CA3111380A1 (es) |
CL (1) | CL2021000757A1 (es) |
CO (1) | CO2021003944A2 (es) |
CR (1) | CR20210153A (es) |
EA (1) | EA202190886A1 (es) |
EC (1) | ECSP21021381A (es) |
IL (1) | IL281812A (es) |
JO (1) | JOP20210058A1 (es) |
MA (1) | MA53721A (es) |
MX (1) | MX2021003737A (es) |
NI (1) | NI202100023A (es) |
PE (1) | PE20211773A1 (es) |
PH (1) | PH12021550659A1 (es) |
SG (1) | SG11202102281VA (es) |
TW (1) | TW202028198A (es) |
WO (1) | WO2020065613A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | P2x7調節劑 |
TW202028198A (zh) | 2018-09-28 | 2020-08-01 | 比利時商健生藥品公司 | 單醯基丙三醇脂酶調節劑 |
US20200102311A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol Lipase Modulators |
MX2022003819A (es) * | 2019-09-30 | 2022-05-11 | Janssen Pharmaceutica Nv | Ligandos de pet de mgl radiomarcados. |
WO2021191359A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
WO2022150962A1 (en) | 2021-01-12 | 2022-07-21 | Westlake Pharmaceutical (Hangzhou) Co., Ltd. | Protease inhibitors, preparation, and uses thereof |
AR127955A1 (es) | 2021-12-16 | 2024-03-13 | Hoffmann La Roche | Nuevos compuestos heterocíclicos |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4812462A (en) | 1986-04-01 | 1989-03-14 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity |
US4816463A (en) | 1986-04-01 | 1989-03-28 | Warner-Lambert Company | Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity |
WO1992005784A1 (en) | 1990-10-02 | 1992-04-16 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists |
JP2005537290A (ja) | 2002-07-25 | 2005-12-08 | ファルマシア・イタリア・エス・ピー・エー | キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物 |
AU2003244632A1 (en) | 2002-07-25 | 2004-02-25 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
FR2857363B1 (fr) | 2003-07-10 | 2007-09-07 | Aventis Pharma Sa | 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation |
AR045037A1 (es) | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
JP2008510810A (ja) | 2004-08-23 | 2008-04-10 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療または予防のためのジペプチジルペプチダーゼ−iv阻害剤としての縮合トリアゾール誘導体 |
WO2006080884A1 (en) | 2005-01-27 | 2006-08-03 | Astrazeneca Ab | Novel biaromatic compounds, inhibitors of the p2x7-receptor |
US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
WO2006110516A1 (en) | 2005-04-11 | 2006-10-19 | Abbott Laboratories | Acylhydrazide p2x7 antagonists and uses thereof |
US7943617B2 (en) | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
PE20090418A1 (es) | 2007-06-21 | 2009-04-18 | Schering Corp | Derivados de guanina policiclicos y sus metodos de uso |
WO2009023623A1 (en) | 2007-08-10 | 2009-02-19 | H, Lundbeck A/S | Heteroaryl amide analogues |
FR2921342B1 (fr) | 2007-09-20 | 2010-03-12 | Airbus France | Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef |
EP2090576A1 (en) | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
CN102066360B (zh) | 2008-04-22 | 2013-10-30 | 詹森药业有限公司 | 喹啉或异喹啉取代的p2x7拮抗剂 |
JP5063815B2 (ja) | 2008-11-25 | 2012-10-31 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体 |
WO2010066629A2 (en) | 2008-12-09 | 2010-06-17 | F. Hoffmann-La Roche Ag | Novel azaindoles |
EP2421535A1 (en) * | 2009-04-22 | 2012-02-29 | Janssen Pharmaceutica N.V. | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors |
WO2010125102A1 (en) | 2009-04-29 | 2010-11-04 | Glaxo Group Limited | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS |
GB0907515D0 (en) | 2009-04-30 | 2009-06-10 | Glaxo Group Ltd | Compounds |
US8871760B2 (en) | 2009-09-21 | 2014-10-28 | Roche Palo Alto Llc | [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators |
JP5848251B2 (ja) | 2009-10-23 | 2016-01-27 | ヤンセン ファーマシューティカ エヌ.ベー. | オレキシン受容体調節因子としての縮合複素環式化合物 |
WO2011103715A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
JP5822911B2 (ja) | 2010-04-02 | 2015-11-25 | ユーロスクリーン エス.エー. | 新規のnk−3受容体選択的アンタゴニスト化合物、医薬組成物、及びnk−3受容体媒介疾患における使用方法 |
US20110252717A1 (en) | 2010-04-16 | 2011-10-20 | Graf Fernandez Rodrigo | Foldable structures for a construction |
WO2012040048A2 (en) | 2010-09-21 | 2012-03-29 | Schering Corporation | Triazolopyrazinones as p2x7 receptor antagonists |
US9586962B2 (en) | 2011-04-20 | 2017-03-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators |
US9273947B2 (en) | 2012-02-07 | 2016-03-01 | Lg Innotek Co., Ltd. | Sensing magnet apparatus for motor |
US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
AU2013266398A1 (en) | 2012-05-22 | 2015-01-22 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
AU2013331380B2 (en) | 2012-10-15 | 2018-03-22 | Epizyme, Inc. | Substituted benzene compounds |
SI2909192T1 (sl) | 2012-10-16 | 2017-08-31 | Janssen Pharmaceutica Nv | Metilensko vezani kinolinilni modulatorji za ROR-gama-t |
KR20150074193A (ko) | 2012-11-01 | 2015-07-01 | 인사이트 코포레이션 | Jak 억제제로서 트리사이클릭 융합된 티오펜 유도체 |
US9796729B2 (en) | 2012-11-23 | 2017-10-24 | Glaxosmithkline Llc | Compounds as diacylglycerol acyltransferase inhibitors |
SG11201504754QA (en) | 2012-12-21 | 2015-07-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
JP6273621B2 (ja) | 2012-12-21 | 2018-02-07 | セルジーン クオンティセル リサーチ,インク. | ヒストンデメチラーゼ阻害剤 |
TW201446745A (zh) | 2013-02-08 | 2014-12-16 | Celgene Avilomics Res Inc | Erk抑制劑及其用途 |
JO3516B1 (ar) | 2013-03-06 | 2020-07-05 | Janssen Pharmaceutica Nv | مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4 |
NO335177B1 (no) | 2013-03-06 | 2014-10-13 | Cambi Technology As | Fremgangsmåte og anordning for termisk biologisk nedbryting og avvanning av biomasse |
SG11201506245QA (en) | 2013-03-14 | 2015-09-29 | Glaxosmithkline Ip No 2 Ltd | 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors |
RU2667509C2 (ru) | 2013-03-14 | 2018-09-21 | Ньюлинк Джинетикс Корпорейшин | Трициклические соединения в качестве ингибиторов иммуносупрессии, опосредуемой метаболизированием триптофана |
EP2970283B1 (en) | 2013-03-14 | 2020-11-11 | Boehringer Ingelheim International GmbH | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
WO2014152537A1 (en) | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | P2x7 modulators |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | P2x7調節劑 |
JO3383B1 (ar) | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
EP2970271B1 (en) | 2013-03-14 | 2017-11-08 | Janssen Pharmaceutica NV | P2x7 modulators |
TWI627174B (zh) | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | P2x7調控劑 |
CN105209449B (zh) | 2013-03-14 | 2019-02-01 | 库拉德夫制药私人有限公司 | 犬尿氨酸途径的抑制剂 |
EP2989103B1 (en) | 2013-03-29 | 2019-02-20 | Ogeda Sa | N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders |
CA2921881A1 (en) | 2013-08-22 | 2015-02-26 | F. Hoffmann-La Roche Ag | Alkynyl alcohols and methods of use |
NZ730334A (en) | 2014-09-11 | 2023-01-27 | Janssen Pharmaceutica Nv | Substituted 2-azabicycles and their use as orexin receptor modulators |
JP6592510B2 (ja) | 2014-09-12 | 2019-10-16 | ヤンセン ファーマシューティカ エヌ.ベー. | P2x7調節因子 |
US20180118749A1 (en) | 2014-09-12 | 2018-05-03 | Janssen Pharmaceutica Nv | P2x7 modulators |
WO2017087858A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
US20200102311A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol Lipase Modulators |
TW202028198A (zh) | 2018-09-28 | 2020-08-01 | 比利時商健生藥品公司 | 單醯基丙三醇脂酶調節劑 |
CN112272670B (zh) | 2019-04-16 | 2023-12-12 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
MX2022003819A (es) | 2019-09-30 | 2022-05-11 | Janssen Pharmaceutica Nv | Ligandos de pet de mgl radiomarcados. |
WO2021191359A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
-
2019
- 2019-09-27 TW TW108135035A patent/TW202028198A/zh unknown
- 2019-09-27 KR KR1020217012874A patent/KR20210069080A/ko unknown
- 2019-09-27 WO PCT/IB2019/058240 patent/WO2020065613A1/en active Application Filing
- 2019-09-27 PE PE2021000405A patent/PE20211773A1/es unknown
- 2019-09-27 JO JOP/2021/0058A patent/JOP20210058A1/ar unknown
- 2019-09-27 US US16/586,088 patent/US20200102303A1/en not_active Abandoned
- 2019-09-27 AU AU2019350624A patent/AU2019350624A1/en active Pending
- 2019-09-27 EA EA202190886A patent/EA202190886A1/ru unknown
- 2019-09-27 JP JP2021517202A patent/JP2022502424A/ja active Pending
- 2019-09-27 MA MA053721A patent/MA53721A/fr unknown
- 2019-09-27 CR CR20210153A patent/CR20210153A/es unknown
- 2019-09-27 BR BR112021005896-6A patent/BR112021005896A2/pt unknown
- 2019-09-27 CA CA3111380A patent/CA3111380A1/en active Pending
- 2019-09-27 CN CN201980078969.1A patent/CN113164459A/zh active Pending
- 2019-09-27 SG SG11202102281VA patent/SG11202102281VA/en unknown
- 2019-09-27 EP EP19780427.1A patent/EP3856178A1/en active Pending
- 2019-09-27 MX MX2021003737A patent/MX2021003737A/es unknown
-
2020
- 2020-12-23 US US17/132,313 patent/US11820766B2/en active Active
-
2021
- 2021-03-22 PH PH12021550659A patent/PH12021550659A1/en unknown
- 2021-03-25 CL CL2021000757A patent/CL2021000757A1/es unknown
- 2021-03-25 IL IL281812A patent/IL281812A/en unknown
- 2021-03-26 EC ECSENADI202121381A patent/ECSP21021381A/es unknown
- 2021-03-26 NI NI202100023A patent/NI202100023A/es unknown
- 2021-03-29 CO CONC2021/0003944A patent/CO2021003944A2/es unknown
-
2022
- 2022-12-06 US US18/062,484 patent/US20230145249A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3111380A1 (en) | 2020-04-02 |
WO2020065613A1 (en) | 2020-04-02 |
CR20210153A (es) | 2021-05-11 |
US20230145249A1 (en) | 2023-05-11 |
PH12021550659A1 (en) | 2022-02-21 |
IL281812A (en) | 2021-05-31 |
US20200102303A1 (en) | 2020-04-02 |
ECSP21021381A (es) | 2021-04-29 |
EA202190886A1 (ru) | 2021-09-07 |
SG11202102281VA (en) | 2021-04-29 |
JOP20210058A1 (ar) | 2021-03-24 |
US11820766B2 (en) | 2023-11-21 |
TW202028198A (zh) | 2020-08-01 |
CN113164459A (zh) | 2021-07-23 |
MA53721A (fr) | 2021-09-15 |
US20220332713A1 (en) | 2022-10-20 |
EP3856178A1 (en) | 2021-08-04 |
BR112021005896A2 (pt) | 2021-07-27 |
MX2021003737A (es) | 2021-05-14 |
PE20211773A1 (es) | 2021-09-08 |
JP2022502424A (ja) | 2022-01-11 |
CL2021000757A1 (es) | 2021-08-27 |
NI202100023A (es) | 2021-09-07 |
AU2019350624A1 (en) | 2021-03-18 |
KR20210069080A (ko) | 2021-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021003944A2 (es) | Moduladores de monoacilglicerol lipasa | |
ECSP22062460A (es) | Moduladores de la monoacilglicerol lipasa | |
MX2021003661A (es) | Moduladores de la monoacilglicerol lipasa. | |
DOP2022000278A (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
MX2022011902A (es) | Moduladores de la monoacilglicerol lipasa. | |
CO2020002959A2 (es) | Moduladores de piruvato quinasas y uso de los mismos | |
CO2017012859A2 (es) | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1 | |
AR057887A1 (es) | Composiciones y metodos de tratamiento de trastornos del snc | |
MX2022011903A (es) | Azaspirociclos como moduladores de monoacilglicerol lipasa. | |
MX2022011904A (es) | Aminociclobutanos como moduladores de monoacilglicerol lipasa. | |
DOP2019000076A (es) | DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO | |
CO2022008675A2 (es) | Derivados bicíclicos sustituidos de piperidina útiles como activadores de células t | |
CL2021002946A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
CL2020001564A1 (es) | Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina. | |
JOP20200272A1 (ar) | مُعدّلات تفارغية سبيروبيريدين لمستقبلات أستيل كولين نيكوتينية | |
CR20130670A (es) | Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth2 | |
CL2023001195A1 (es) | Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades. | |
EA201992127A1 (ru) | ФАРМАКОЛОГИЧЕСКИ АКТИВНЫЕ АЛИЦИКЛИЧЕСКИ ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА | |
UY38304A (es) | Dinucleótidos cíclicos como agonistas de sting y composiciones farmacéuticas que los contienen | |
PE20230106A1 (es) | Compuestos de pirimidina fusionados como moduladores de kcc2 | |
CO6280529A2 (es) | DERIVADOS DE AMIDA AROMÁTICOS DE ÁCIDO PENTANOICO COMO MODULADORES DE γ - SECRETOSA | |
CL2023000352A1 (es) | Derivados de pirazolo[1,5-a]pirimidina sustituidos con heterocíclicos farmacológicamente activos | |
CO2021017740A2 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
ECSP22003596A (es) | Moduladores del receptor de nmda | |
CL2022002989A1 (es) | Imidazopiridazinas como moduladores de il-17. |